Women treated with tamoxifen [2,12,13,14] or aromatase inhibitors [15] as endocrine therapies to prevent recurrence of estrogen receptor α positive (ERα+) breast cancer have a higher prevalence of NAFLD, notably in the context of obesity [16]. This evidence concerns the gene ESR1 and breast cancer.